SequelSEC

Exousia Bio, Inc. LMMY

Services-Educational Services · CIK 0001939937 · Fiscal year ends 0531

Revenue
$0
Fiscal year ended 2026-02-28
Operating income
Unavailable
Fiscal year ended 2026-02-28
Free cash flow
Unavailable
Fiscal year ended 2026-02-28

Valuation, from the filing

Public float$1.29MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-11-30
Float per share$0.17Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income25.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue343.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-11-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-05-31 — the year that filing covered.

How this compares in its industry

Percentile among the Services-Educational Services filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Effective tax rate0.0%0th
Gross margin-93.4%0th
Net margin1370.5%100th
Revenue YoY growth-67.4%0th

Exousia Bio, Inc. (LMMY) reported revenue of $0 and net income of -$80.16K for the fiscal year ended 2026-02-28. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Exousia Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Educational Services.

Income

Exousia Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-28
Revenue$0
Cost of revenue$69.36K
Gross profit-$69.36K
Operating incomeUnavailable
Net income-$80.16K
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$80.16K
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Exousia Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-28
Cash & equivalentsUnavailable
Total assets$22.05M
Current assets$0
Total liabilities$261.02K
Current liabilities$261.02K
Total equity incl. NCI$21.79M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$0
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$212.30K

Cash flow

Exousia Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-28
Operating cash flow$85.56K
Capital expendituresUnavailable
Investing cash flow-$22.05M
Financing cash flow$21.96M
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Exousia Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-02-28
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.00x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LMMY in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-06-16View SEC filing
10-Q · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-17View SEC filing
10-K · Filed 2025-10-17View SEC filing
10-Q · Filed 2025-04-24View SEC filing
10-Q · Filed 2025-01-10View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.